Patents Represented by Attorney, Agent or Law Firm Elizabeth A. Dawalt
-
Patent number: 6417193Abstract: The present invention relates to a compound of formula (I) which is useful for inhibiting resistant neoplasms where the resistance is conferred in part or in total by MRP1.Type: GrantFiled: September 13, 2000Date of Patent: July 9, 2002Assignee: Eli Lilly and CompanyInventors: Joseph M Gruber, Bryan H Norman
-
Patent number: 6369070Abstract: The present invention relates to a compound of formula (I), which is useful for inhibiting resistant neoplasms where the resistance is conferred in part or in total by MRP1.Type: GrantFiled: September 13, 2000Date of Patent: April 9, 2002Assignee: Eli Lilly and CompanyInventors: Joseph M. Gruber, Julian S Kroin, Bryan H Norman
-
Patent number: 6358994Abstract: This invention provides compounds of the Formula I: which are useful as tachykinin receptor antagonists. This invention also provides methods employing these compounds, as well as pharmaceutical formulations comprising these compounds.Type: GrantFiled: January 27, 2000Date of Patent: March 19, 2002Assignee: Eli Lilly and CompanyInventors: James E Fritz, Philip A Hipskind, Stephen W Kaldor, Karen L Lobb, James A Nixon
-
Patent number: 6339094Abstract: This invention provides a series of substituted propanamines useful as tachykinin receptor antagonists. This invention also provides methods employing these substituted propanamines as well as pharmaceutical formulations comprising these compounds.Type: GrantFiled: January 27, 2000Date of Patent: January 15, 2002Assignee: Eli Lilly and CompanyInventors: James E Fritz, Philip A Hipskind, Stephen W Kaldor, Karen L Lobb, James A Nixon
-
Patent number: 6268500Abstract: The present invention relates to a process for preparing 5-nitroquinoline hydrohalide comprising: (A) heating a slurry comprising a mixture of nitroquinoline position isomer hydrohalide salts in wet dimethylformamide to form a solution; (B) cooling the solution of Step (A) until a precipitate comprising 5-nitroquinoline hydrohalide is formed; and (C) collecting the precipitate.Type: GrantFiled: January 9, 1998Date of Patent: July 31, 2001Assignee: Eli Lilly and CompanyInventors: Thomas J. Kress, James P. Wepsiec
-
Patent number: 6262262Abstract: The present application relates to a series of novel sulfonic acid metal cation salts of the formula which are useful intermediates to prepare antifolate 5-substituted pyrrolo[2,3-d]pyrimidines. The present invention also relates to a novel process for preparing the sulfonic acid metal cation salts and to a novel process for preparing aldehydes of the formula from the corresponding sulfonic acid metal cation salts.Type: GrantFiled: February 15, 2000Date of Patent: July 17, 2001Assignee: Eli Lilly and CompanyInventor: Douglas Patton Kjell
-
Patent number: 6239144Abstract: The present invention provides methods of treating or preventing conditions associated with a lack of parathyroid hormone comprising administering to a mammal in need thereof an effective amount of a compound having activity as a tachykinin receptor antagonist. In a most preferred embodiment the present invention provides methods of increasing bone growth in a mammal which comprises administering to a mammal in need thereof an effective amount of a compound having activity as a tachykinin receptor antagonist. Another embodiment of this invention provides methods of treating hyperparathyroidism in a mammal comprising administering to a mammal in need thereof an effective amount of a compound having activity as a tachykinin receptor antagonist.Type: GrantFiled: May 27, 1999Date of Patent: May 29, 2001Assignee: Eli Lilly and CompanyInventors: Rachelle J Galvin, Bruce D Gitter
-
Patent number: 6180633Abstract: Drug and multidrug resistant modulators of the formula: where R1 and R2 are independently hydrogen or halo; A is —CH2—CH2—, —CH2—CHR4—CH2—, or —CH2—CHR5—CHR6—CH2—, where R4 is —H, —OH, or acyloxy; one of R5 or R6 is —H, —OH, or acyloxy, and the other is —H; R3 is a polyaryl; and pharmaceutically acceptable salts and solvates thereof, are described and claimed. Use of the new compounds in the preparation of pharmaceutical compositions is described and claimed. In addition, methods for treating drug and multidrug resistance in various diseases using a compound, or pharmaceutically acceptable salt or solvate thereof, of this invention are described and claimed.Type: GrantFiled: June 30, 1999Date of Patent: January 30, 2001Assignee: Eli Lilly and CompanyInventors: Julian Stanley Kroin, Bryan Hurst Norman
-
Patent number: 6130219Abstract: Drug and multidrug resistant modulators of the formula: ##STR1## where R.sup.1 and R.sup.2 are independently hydrogen or halo; A is --CH.sub.2 --CH.sub.2 --, --CH.sub.2 --CHR.sup.4 --CH.sub.2 --, or --CH.sub.2 --CHR.sup.5 --CHR.sup.6 --CH.sub.2 --, where R.sup.4 is --H, --OH, or acyloxy; one of R.sup.5 or R.sup.6 is --H, --OH, or acyloxy, and the other is --H; R.sup.3 is a polyaryl; and pharmaceutically acceptable salts and solvates thereof, are described and claimed. Use of the new compounds in the preparation of pharmaceutical compositions is described and claimed. In addition, methods for treating drug and multidrug resistance in various diseases using a compound, or pharmaceutically acceptable salt or solvate thereof, of this invention are described and claimed. Also, methods of enhancing oral bioavailability of a drug and methods of enhancing bioavailability of a drug to the brain using a compound, or pharmaceutically acceptable salt or solvate thereof, of this invention are described and claimed.Type: GrantFiled: June 30, 1999Date of Patent: October 10, 2000Assignee: Eli Lilly and CompanyInventors: Julian Stanley Kroin, Bryan Hurst Norman
-
Patent number: 6124311Abstract: The present invention provides methods for reversing multidrug resistance in a resistant neoplasm by treating a mammal in need of said treatment with a substituted indole, benzofuran, benzothiophene, naphthalene, or dihydronaphthalene. This invention also provides methods for treating neoplasms in a mammal which comprises administering to a mammal in need of this treatment a substituted indole, benzofuran, benzothiophene, naphthalene, or dihydronaphthalene in combination with an oncolytic agent.Type: GrantFiled: June 28, 1996Date of Patent: September 26, 2000Assignee: Eli Lilly and CompanyInventors: Srinivasan Chandrasekhar, Anne H. Dantzig, Robert L. Shepard, James J. Starling, Mark A. Winter
-
Patent number: 6121292Abstract: The present invention provides methods for reversing multidrug resistance in a resistant neoplasm by treating a mammal in need of said treatment with a substituted indole, benzofuran, benzothiophene, naphthalene, or dihydronaphthalene. This invention also provides methods for treating neoplasms in a mammal which comprises administering to a mammal in need of this treatment a substituted indole, benzofuran, benzothiophene, naphthalene, or dihydronaphthalene in combination with an oncolytic agent.Type: GrantFiled: June 28, 1996Date of Patent: September 19, 2000Assignee: Eli Lilly and CompanyInventors: Srinivasan Chandrasekhar, Anne H. Dantzig, Robert L. Shepard, James J. Starling, Mark A. Winter
-
Patent number: 6025379Abstract: This invention provides methods for the treatment or prevention of interstitial cystitis or urethral syndrome in a mammal which comprise administering to a mammal in need thereof an effective amount of a substituted benzimidazole, or a pharmaceutically acceptable salt or solvate thereof.Type: GrantFiled: August 25, 1998Date of Patent: February 15, 2000Assignee: Eli Lilly and CompanyInventors: Smriti Iyengar, Mark A. Muhlhauser, Karl B. Thor
-
Patent number: 6025359Abstract: Drug and multidrug resistant modulators of the formula: ##STR1## where R.sup.1 and R.sup.2 are independently hydrogen or halo; A is --CH.sub.2 --CH.sub.2 --, --CH.sub.2 --CHR.sup.4 --CH.sub.2 --, or --CH.sub.2 --CHR.sup.5 --CHR.sup.6 --CH.sub.2 --, where R.sup.4 is --H, --OH, or acyloxy; one of R.sup.5 or R.sup.6 is --H, --OH, or acyloxy, and the other is --H; R.sup.3 is a polyaryl; and pharmaceutically acceptable salts and solvates thereof, are described and claimed. Use of the new compounds in the preparation of pharmaceutical compositions is described and claimed. In addition, methods for treating drug and multidrug resistance in various diseases using a compound, or pharmaceutically acceptable salt or solvate thereof, of this invention are described and claimed. Also, methods of enhancing oral bioavailability of a drug and methods of enhancing bioavailability of a drug to the brain using a compound, or pharmaceutically acceptable salt or solvate thereof, of this invention are described and claimed.Type: GrantFiled: June 12, 1997Date of Patent: February 15, 2000Assignee: Eli Lilly and CompanyInventors: Julian Stanley Kroin, Bryan Hurst Norman
-
Patent number: 6022980Abstract: This invention provides an improved process for the preparation and separation of 4-halo and 6-halomelatonins.Type: GrantFiled: May 13, 1999Date of Patent: February 8, 2000Assignee: Eli Lilly and CompanyInventor: Michael Edward Flaugh
-
Patent number: 6017930Abstract: This invention provides methods for the treatment or prevention of interstitial cystitis or urethral syndrome in a mammal which comprise administering to a mammal in need thereof an effective amount of a compound of formula (I), where R.sup.1 and R.sup.2 are independently selected from the group consisting of hydrogen, methyl, methoxy, chloro, and trifluoromethyl, with the proviso that no more than one of R.sup.1 and R.sup.2 can be hydrogen; and Y is (1), (2), (3), (4), (5), (6), N--R.sup.a, or CH--NR.sup.b R.sup.c, where R.sup.a, R.sup.b, and R.sup.c are independently selected from the group consisting of hydrogen and C.sub.1 -C.sub.6 alkyl; or a pharmaceutically acceptable salt or solvate thereof.Type: GrantFiled: August 25, 1998Date of Patent: January 25, 2000Assignee: Eli Lilly and CompanyInventors: Smriti Iyengar, Mark A. Muhlhauser, Karl B. Thor
-
Patent number: 6001837Abstract: This invention provides methods for the treatment or prevention of sleep apnea in a mammal which comprise administering to a mammal in need thereof an effective amount of a compound of formula (I) where R.sup.1 and R.sup.2 are independently selected from the group consisting of hydrogen, methyl, methoxy, chloro, and trifluoromethyl, with the proviso that no more than one of R.sup.1 and R.sup.2 can be hydrogen; and Y is (a), (b), (c), (d), (e), (f), N-R.sup.a, or CH-NR.sup.b R.sub.c, where R.sup.a, R.sup.b, and R.sup.c are independently selected from the group consisting of hydrogen and C.sub.1 -C.sub.6 alkyl; or a pharmaceutically acceptable salt or solvate thereof.Type: GrantFiled: August 27, 1998Date of Patent: December 14, 1999Assignee: Eli Lilly and CompanyInventors: Bruce D. Gitter, Smriti Iyengar